Equities research analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report sales of $9.93 million for the current quarter, according to Zacks. Three analysts have provided estimates for Amicus Therapeutics’ earnings, with the highest sales estimate coming in at $10.08 million and the lowest estimate coming in at $9.76 million. Amicus Therapeutics posted sales of $2.13 million in the same quarter last year, which would indicate a positive year over year growth rate of 366.2%. The firm is scheduled to report its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that Amicus Therapeutics will report full year sales of $9.93 million for the current fiscal year, with estimates ranging from $32.90 million to $37.13 million. For the next financial year, analysts forecast that the business will report sales of $93.45 million per share, with estimates ranging from $69.78 million to $115.84 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter in the prior year, the business earned ($0.40) earnings per share.

FOLD has been the subject of a number of recent research reports. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. BidaskClub cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Bank of America Corporation dropped their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, May 25th. Cowen and Company reiterated a “buy” rating and issued a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a report on Friday, June 30th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and an average price target of $14.58.

Amicus Therapeutics (FOLD) traded down 0.23% on Friday, hitting $13.10. 1,805,324 shares of the stock were exchanged. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $14.05. The company has a 50-day moving average price of $12.85 and a 200-day moving average price of $9.00. The firm’s market cap is $2.16 billion.

In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average cost of $12.25 per share, with a total value of $18,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at $641,840. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of FOLD. Teacher Retirement System of Texas raised its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $124,000. Aperio Group LLC raised its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $145,000.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/26/brokerages-expect-amicus-therapeutics-inc-fold-will-post-quarterly-sales-of-9-93-million.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.